Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | FBP1 | P09467 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10571503 | 0.83 | CA2 (0.55) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL31435391 | 0.81 | AKR1B1 (0.56) | PGRMEN1KMT2AALDH1A1MMP2 | |
| SCHEMBL2199161 | 0.81 | AKR1B1 (0.56) | PGRMEN1KMT2AALDH1A1MMP2 | |
| SCHEMBL8014338 | 0.81 | CA2 (0.48) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL4617100 | 0.80 | ALDH1A1 (0.46) | PGRMEN1KMT2AALDH1A1MMP2 | |
| SCHEMBL294450 | 0.79 | PGR (0.53) | PGRMEN1KMT2AALDH1A1MMP2 | |
| SCHEMBL29422524 | 0.79 | ALDH1A1 (0.54) | PGRMEN1KMT2AALDH1A1MMP2 | |
| SCHEMBL8477676 | 0.79 | ALDH1A1 (0.59) | PGRMEN1KMT2AALDH1A1MMP2 | |
| SCHEMBL294451 | 0.79 | ALDH1A1 (0.59) | PGRMEN1KMT2AALDH1A1MMP2 | |
| SCHEMBL16000 | 0.79 | ALDH1A1 (0.54) | PGRMEN1KMT2AALDH1A1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016792-A1 | MUSCARINIC M2 RECEPTOR BLOCKADE TO DELAY OR PREVENT ONSET OF PROGRESSIVE MEMORY DECLINE | US GOV VETERANS AFFAIRS (US) | 2024-01-18 | — | — | US | disclosed |
| US-11801241-B2 | Muscarinic M2 receptor blockade to delay or prevent onset of progressive memory decline | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2023-10-31 | — | — | US | disclosed |
| US-20180256559-A1 | MUSCARINIC M2 RECEPTOR BLOCKADE TO DELAY OR PREVENT ONSET OF PROGRESSIVE MEMORY DECLINE | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2018-09-13 | — | — | US | disclosed |
| EP-2081890-B1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-01-12 | — | — | EP | disclosed |
| EP-2081890-B1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-7776910-B2 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776910-B2 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776910-B2 | Arylsulfonyl pyrrolidines as 5-HT6 inhibitors | ROCHE PALO ALTO LLC (US) | 2010-08-17 | — | — | US | disclosed |
| EP-2081890-A1 | ARYLSULFONYL PYRROLIDINES AS 5-HT6 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-07-29 | — | — | EP | disclosed |
| US-20080318933-A1 | 5-Sulfonyl-1-Piperidinyl Substituted Indole Derivatives as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders | GLAXO GROUP LIMITED | 2008-12-25 | — | — | US | disclosed |
| EP-1814873-A2 | 5-SULFONYL-1-PIPERIDINYL SUBSTITUTED INDOLE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006038006-A2 | 5-SULFONYL-1-PIPERIDINYL SUBSTITUTED INDOLE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-04-13 | — | — | WO | disclosed |
| CN-1167682-C | Muscarinic antagonists | ���鹫˾ | 2004-09-22 | — | — | CN | disclosed |
| EP-1214299-B1 | MUSCARINIC ANTAGONISTS | SCHERING CORP (US) | 2004-04-14 | — | — | EP | disclosed |
| CN-1374949-A | Muscarinic antagonists | SCHERING CORP (US) | 2002-10-16 | — | — | CN | disclosed |
| EP-1214299-A1 | MUSCARINIC ANTAGONISTS | SCHERING CORPORATION (US) | 2002-06-19 | — | — | EP | disclosed |
| US-6294554-B1 | AMINEAMIDE HETEROCYCLIC SULFONATE AMINES | SCHERING CORPORATION | 2001-09-25 | — | — | US | disclosed |
| WO-2001021590-A1 | MUSCARINIC ANTAGONISTS | SCHERING CORPORATION (US) | 2001-03-29 | — | — | WO | disclosed |
| CN-1161040-A | Bicyclic tetrahydro pyrazolopyridines and their use as medicaments | PFIZER (US) | 1997-10-01 | — | — | CN | disclosed |
| US-4060549-A | Process for preparing sulfonic acid fluorides | BAYER AKTIENGESELLSCHAFT (DT) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318933-A1 | 5-Sulfonyl-1-Piperidinyl Substituted Indole Derivatives as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders | HTR6, HTR5A, TPH1 | PGR 1500/4885MEN1 1607/4885KMT2A 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.